SCHEDULE: Squadron Master Fund Discloses 6.5% Stake in Spruce Biosciences

Squadron Master Fund LP and its affiliates have reported a 6.5% beneficial ownership stake in Spruce Biosciences, Inc., holding 70,000 shares of common stock.

Summary

• Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank collectively reported beneficial ownership of 70,000 shares of Spruce Biosciences, Inc. common stock.
• This represents 6.5% of the company's outstanding common stock, based on 1,070,370 shares as of November 7, 2025.
• The reporting persons share both voting and dispositive power over all 70,000 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Spruce Biosciences, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional stake by Squadron Master Fund LP suggests confidence in Spruce Biosciences, Inc. without indicating an activist intent.

Positives

• A significant institutional investor, Squadron Master Fund LP, has taken a 6.5% stake in Spruce Biosciences, indicating confidence in the company's long-term prospects.
• The investment is stated to be for ordinary course of business, suggesting a passive investment rather than an activist stance that could create uncertainty.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional investment in biotechnology companies like Spruce Biosciences often signals a belief in the long-term potential of their drug pipelines or market position. A 6.5% stake by Squadron Master Fund LP suggests a notable commitment, which could be viewed positively by the market, especially in a sector known for high R&D costs and regulatory hurdles.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a 6.5% stake could instill confidence and potentially attract other investors, positively impacting share price.
• Company Management: The presence of a large institutional holder may lead to increased scrutiny or engagement, though the filing states the investment is passive.

Key Dates

Recommendation

The disclosure of a 6.5% beneficial ownership by Squadron Master Fund LP is a positive signal of institutional confidence in Spruce Biosciences. However, without additional financial or operational updates, a 'hold' recommendation is prudent, acknowledging the positive sentiment while awaiting further fundamental catalysts.

Keywords

Spruce Biosciences, Squadron Master Fund, Squadron Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investment, Biotechnology, Healthcare